Kaya Ltd

- The company is evaluating options to capitalize the business and intends to provide updates in the coming months (Page 5). - No specific timelines or guidance have been given yet regarding fundraising (Page 5). - As of December 31, the outstanding external loan was INR 12 crores, and director loans stood at approximately INR 93.7 crores, totaling about INR 105 crores in net debt (Page 7). - No new director loans were taken in the current quarter (Page 7). - Management is currently not commenting on funding requirements for growth aspirations but indicated plans may be shared in the future (Page 7). - Clinic expansion capex is limited this year, with plans for more aggressive growth and capital expenditure likely in the next financial year (Page 7).

- Limited expansion capex for the current year, with plans to open no more than 4 new clinics by the end of this financial year. - Plans to strategically expand in Tier 2 cities in the next financial year. - Selective refurbishment of older clinics is underway. - Ongoing replacement and upgrade of dermatological equipment and machines to phase out older technology. - Investments being made in new technology and AI applications to enhance customer consultation and engagement. - Management expects better clarity on capex plans by the end of the current quarter. - Focus on clinic refurbishment, technology refresh, and strategic new clinic openings rather than aggressive expansion in the short term.

- Kaya Limited plans to expand its services beyond skin to include Body and Hair verticals in both India and the Middle East. - Early response to the Body vertical in India is strong, indicating potential growth in that segment. - Plans to open at least 4 new clinics by the end of the financial year, focusing on Tier 2 cities for expansion in the coming years. - Ongoing initiatives include refurbishment of older clinics and technology upgrades, which aim to improve customer experience and sales. - Business growth is supported by marketing automation, digital initiatives, and customer engagement tools to increase footfall and conversions. - Nutraceuticals and product sales through D2C and e-commerce channels are also expected to grow, contributing to overall revenue. - Average transaction size (ATS) is increasing, reflecting higher-value services and packages, which can enhance revenue even with stable or slightly lower customer counts. - Management refrains from giving specific long-term revenue or margin guidance but indicates multiple levers for growth.

- Management refrains from giving specific revenue or margin guidance for the full year or next 3 years, citing uncertainties (Page 5, 8). - Expansion plans include opening 4 new clinics by end of FY '23, with more aggressive growth expected in next financial year, especially targeting Tier 2 cities (Pages 5, 7). - Refurbishment and technology refreshment of existing clinics ongoing to improve operations (Pages 5, 7). - Mature clinics have EBITDA margins around 25-35%, with scope for improvement through top line growth and cost control (Page 9). - Middle East operations currently have lower EBITDA margins (~25%) due increased investments in staffing, but expected to improve as revenue grows (Page 9). - Initiatives include marketing automation, digital channels, and expansion into Body and Hair services expected to drive higher transaction values and EBITDA (Pages 7, 8). - Overall, earnings growth expected to come from mix of clinic expansion, service diversification, and operational efficiencies, but no precise EPS targets were disclosed.

The transcript does not specifically mention the current or expected order book or pending orders for Kaya Limited. However, some related insights include: - Expansion plans include opening 4 new clinics by the end of the current financial year and additional clinics in the next couple of years, with focus on Tier 2 cities. - Capital expenditure this year is limited due to planned opening of only 4 clinics; next year plans include refurbishment and tech upgrades. - No clear data on order book or pending orders was provided during the call. - Fundraising plans and capitalization options are being evaluated, with updates expected over the next few months. If you are seeking order backlog details, they are not disclosed in this earnings call transcript.